Genocea Biosciences Inc. (NASDAQ:GNCA) shares saw strong trading volume on Wednesday . 1,469,540 shares traded hands during mid-day trading, an increase of 63% from the previous session’s volume of 902,000 shares.The stock last traded at $4.39 and had previously closed at $4.16.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 12th. FBR & Co reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Genocea Biosciences in a research note on Friday, April 1st. Stifel Nicolaus lifted their price objective on shares of Genocea Biosciences from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Friday, April 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Genocea Biosciences in a research note on Friday, April 1st. Six research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $18.13.

The stock’s market cap is $123.59 million. The company’s 50 day moving average is $4.16 and its 200 day moving average is $4.37.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.07. Analysts expect that Genocea Biosciences Inc. will post ($1.74) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Genocea Biosciences stock. AWM Investment Company Inc. raised its stake in shares of Genocea Biosciences Inc. (NASDAQ:GNCA) by 45.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 715,000 shares of the company’s stock after buying an additional 222,900 shares during the period. AWM Investment Company Inc. owned 2.54% of Genocea Biosciences worth $3,768,000 as of its most recent SEC filing.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.